Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design

Drug Development and Industrial Pharmacy

Volumn 41, Issue 12, 2015, Pages 1968-1977

  Dudhipala, Narendar ^a   Veerabrahma, Kishan ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Central composite design; Nisoldipine; Pharmacodynamics; Pharmacokinetics; Solid lipid nanoparticles

Indexed keywords

NISOLDIPINE; PHOSPHATIDYLCHOLINE; SOLID LIPID NANOPARTICLE; ANTIHYPERTENSIVE AGENT; DRUG CARRIER; LIPID; NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG RELEASE; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PHARMACOKINETICS; PHOTON CORRELATION SPECTROSCOPY; PLASMA CONCENTRATION-TIME CURVE; RAT; SCANNING ELECTRON MICROSCOPY; SYSTOLIC BLOOD PRESSURE; X RAY DIFFRACTION; X RAY POWDER DIFFRACTION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DRUG DESIGN; METABOLISM; SYNTHESIS; WISTAR RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG CARRIERS; DRUG DESIGN; LIPIDS; MALE; NANOPARTICLES; NISOLDIPINE; PARTICLE SIZE; RATS; RATS, WISTAR; X-RAY DIFFRACTION;

EID: 84949604505     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2015.1024685     Document Type: Article

References (34)

1. Mehnert W, Mäder K. Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 2012;64:83-101.
2. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
3. Mühlen AZ, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled release drug delivery - drug release and release mechanism. Eur J Pharm Biopharm 1998;45:149-55.
4. Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release 2008;129:1-10.
5. Zheng W, Jain A, Papoutsakis D, et al. Selection of oral bioavailability enhancing formulations during drug discovery. Drug Dev Ind Pharm 2012;38:235-47.
6. Hamishehkar H, Shokri J, Fallahi S, et al. Histopathological evaluation of caffeine-loaded solid lipid nanoparticles in efficient treatment of cellulite. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi:10.3109/03639045.2014.980426.
7. Khurana S, Jain NK, Bedi PMS. Nanostructured lipid carriers based nanogel for meloxicam delivery: mechanistic, in-vivo and stability evaluation. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi:10.3109/03639045.2014.950586.
8. Arai H, Suzuki T, Kaseda C, Takayama K. Effect of an experimental design for evaluating the nonlinear optimal formulation of theophylline tablets using a bootstrap resampling technique. Chem Pharm Bull 2009;57:572-9.
9. Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic "design of experiments." Part-I: fundamental aspects. Crit Rev Ther Drug Carrier Syst 2005;22:27-105.
10. Nazzal S, Khan M. Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system. AAPS PharmSciTech 2002;3:23-31.
11. Gonzalez-Mira E, Egea M, Souto E, et al. Optimizing flurbiprofenloaded NLC by central composite factorial design for ocular delivery. Nanotechnology 2011;22:95-101.
12. Takanaga H, Ohnishi A, Murakami H, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000;67:201-14.
13. Gupta A, Ram SG, Ganga S. Development, evaluation and optimization of extended release buccal tablets prepared using progressive hydration technology. Int J Drug Deliv 2010;2:37-48.
14. Narendar D, Kishan V. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 2014. [Epub ahead of print]. doi:10.3109/10717544.2014.914986.
15. Hao J, Wang F, Wang X, et al. Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eur J Pharm Sci 2012;47:497-505.
16. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004;95:627-38.
17. Swetha A, Buchi NN. Development and validation of rp-hplc-pda method for the estimation of nisoldipine in bulk and formulations. Ind J Pharm Sci 2012;4:88-91.
18. Kathe N, Henriksen B, Chauhan H. Physicochemical characterization techniques for solid lipid nanoparticles: principles and limitations. Drug Dev Ind Pharm 2014;40:1565-75.
19. Vinay Kumar V, Raghavendra C, Rojarani K, et al. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf B 2012;95:1-9.
20. Howard MD, Lu X, Jay M, Dziubla TD. Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles. Drug Dev Ind Pharm 2012;38:1270-9.
21. Schwarz C, Mehnert W. Freeze-drying of drug-free and drugloaded solid lipid nanoparticles (SLN). Int J Pharm 1997;157:171-9.
22. Madhu B, Raju J, Karthik Yadav J, et al. Enhanced intestinal absorption and bioavailability of raloxifene hydrochloride via lyophilized solid lipid nanoparticles. Adv Powder Technol 2013;24:393-402.
23. Zhang Q, Yang G, Liu H, et al. Preparation of a novel glycidyl methacrylate-based monolith and its application for the determination of m-nisoldipine in human plasma. J Chromatogr Sci 2010;48:517-22.
24. Li M, Wang Q, Wang C, et al. Tissues distribution of R-(+) - and S-(+)-m-nisoldipine after single enantiomer administration in rats. Drug Dev Ind Pharm 2009;35:65-72.
25. Dai S, McNeill JH. Fructose-induced hypertension in rats is concentration- and duration-dependent. J Pharmacol Toxicol Methods 1995;33:101-7.
26. Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987;10:512-16.
27. Sudhir V, Yan L, Rajeev G, Diane JB. Quality by design approach to understand the process of nanosuspension preparation. Int J Pharm 2009;377:185-98.
28. Torrades F, Saiz Z, García-Hortal JA. Using central composite experimental design to optimize the degradation of black liquor by fenton reagent. Desalination 2011;268:97-102.
29. Wang Z, Li Q, Zhao X, et al. Preparation, formulation optimization and antitumor actions of mannitol coupling camptothecin nanoparticles. Int J Pharm 2014;465:360-7.
30. Varshosaz J, Ghaffari S, Khoshay MR, et al. Development and optimization of solid lipid nanoparticles of amikacin by central composite design. J Liposome Res 2010;20:97-104.
31. Liu CH, Wu CT, Fang JY. Characterization and formulation optimization of solid lipid nanoparticles in vitamin K1 delivery. Drug Dev Ind Pharm 2010;36:751-61.
32. Choi MJ, Briancon S, Andrieu J, et al. Effect of freeze-drying process conditions on the stability of nanoparticles. Dry Technol 2004;22:335-46.
33. Dodiya S, Chavhan S, Korde A, Sawant KK. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Drug Dev Ind Pharm 2013;39:733-43.
34. Parveen R, Ahmad FJ, Iqbal Z, et al. Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies. Drug Dev Ind Pharm 2014;40:1206-12.